Program
quemliclustat
Also written as “Quemliclustat” and “AB680”.
Its studies are mostly in Pancreatic Neoplasms · Adenocarcinoma Of Esophagus · Carcinoma, Non-Small-Cell Lung, led by 2 companies.
Drug pageQuemliclustat: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Arcus Biosciencesits history only | 61 open or running | phase 3since Sep 20, 2024 | Sep 18, 2018 | Nov 30, 2030phase 3 · NCT06608927 |
| Gilead Sciences | 11 open or running | phase 2since Dec 9, 2022 | Dec 9, 2022 | Dec 2027phase 2 · NCT05676931 |
Also a collaborator on its studies: Otsuka.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Gilead Sciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 19, 2020Named quemliclustatINNProposed as its International Nonproprietary Name in WHO's List 124 · before, AB680
- Dec 9, 2022First study: phase 2 study in Advanced Non-Small Cell Lung CancerFirst studyNCT05676931 · 400 enrolled · United States, Australia, France and more
Ahead
- Dec 2027Primary completion: phase 2 study in Advanced Non-Small Cell Lung CancerNCT05676931
TargetBeta
“A small molecule, competitive inhibitor of the ectoenzyme CD73 (cluster of differentiation 73; 5'-ecto-nucleotidase; 5'-NT; ecto-5'-nucleotidase), ”NCIt, by rule
Other programs on NT5E
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| oleclumab | AstraZeneca | phase 3 | 8 |
| uliledlimabrule | tj-biopharma-co-ltd | phase 3 | 4 |
Studies
The one study Gilead Sciences leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05676931Advanced Non-Small Cell Lung Cancer · United States, Australia, France and more | 2 | Active, not recruiting | Dec 2027 | 400 |
How it is read
Names in the registry
- “Quemliclustat”, 4 entries
- “AB680”, 3 entries
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 2 studies
- Adenocarcinoma Of Esophagus, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.